The long-term efficacy and safety of sustained-release diltiazem (Tilazem; Parke-Davis) were evaluated. A total of 27 young, physically active patients with hypertension were followed up for 17 months. On a dosage of 90 mg twice daily, adequate blood pressure reduction was obtained in 23 patients (85%). No adverse effects were noted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
long-term efficacy
8
efficacy safety
8
safety sustained-release
8
sustained-release diltiazem
8
diltiazem treatment
4
treatment hypertension
4
hypertension long-term
4
diltiazem tilazem
4
tilazem parke-davis
4
parke-davis evaluated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!